Bensley told Outsourcing-pharma that the firm, which gained a wholesale distributor’s license (WDL) for its facility in Boston, Massachusetts, last month, sees plenty of opportunities in the US market.
“The increasing demand for evidence-based medicine, particularly in today’s economic climate, is resulting in a greater focus on clinical studies comparing investigational drugs against an established standard of care.
Bensley explained that: “Comparator sourcing is a time-intensive process,“ adding that “because we have an established global infrastructure, we can do it far more efficiently and cost effectively than a pharmaceutical company on its own.”
She went on to say that the Boston site which, like Pharmarama’s facility in the UK, houses temperature-controlled storage and distribution capacity, “will enable us to attract more clients.”
However, while the focus of operations at Boston is the US, like Pharmarama sites worldwide the new facility will also serve other regions, including rapidly expanding markets in South and Central America.
The firm also provides comparator pharmaceutical drug sourcing services in the Chinese clinical trials sector through a partnership it set up in 2007 with a firm in Shenzhen.
The increasing global spread of the clinical trials industry and pressure from regulators to prove a drug is more effective than those that are already available is likely to increase demand for comparator medications of the next few years.